Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-Centre Randomised, Double-Blind, Double-Dummy Parallel Group Study of the Onset and Offset of Antiplatelet Effects of AZD6140 Compared With Clopidogrel and Placebo With Aspirin as Background Therapy in Patients With Stable Coronary Artery Disease (CAD).

Next Previous
Trial Profile

A Multi-Centre Randomised, Double-Blind, Double-Dummy Parallel Group Study of the Onset and Offset of Antiplatelet Effects of AZD6140 Compared With Clopidogrel and Placebo With Aspirin as Background Therapy in Patients With Stable Coronary Artery Disease (CAD).

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 10 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ticagrelor (Primary) ; Clopidogrel
  • Indications Arterial thrombosis
  • Focus Therapeutic Use
  • Acronyms ONSET-OFFSET
  • Sponsors AstraZeneca

Most Recent Events

  • 10 Nov 2018 Results characterizing ticagrelor exposure-response relationship for platelet inhibition in patients with stable coronary artery disease (CAD) and a history of myocardial infarction (MI), using non-linear mixed effects modelling and simulation of two trials (NCT00528411 and NCT01225562) published in the British Journal of Clinical Pharmacology
  • 30 Aug 2010 Results have been presented at ESC Congress 2010: Annual Congress of the European Society of Cardiology.
  • 18 Nov 2009 Results on the effects on cardiopulmonary function have been presented at the American Heart Association Scientific Sessions.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top